chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 12.0
Sex: F
Vaccine: FLU4, HPV9, MNQ, TDAP
Symptoms: Expired product administered
Clinical narrative: Patient's arms were sore for a couple of days due to receiving 2 shots in each; Information has been received from FDA (VAERS number 863223 - 1) on 18-AUG-2022.  This spontaneous report was received from healthcare professional/staff and refers to a  non-pregnant 12-year-old female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported.   On 19-FEB-2020, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9), dose number in series reported as not applicable (N/A), lot # R023606, expiration date was not reported but upon internal validation established as 06-MAY-2021, administered intramuscularly in right arm (strength and dose were not provided). On the same date, the patient was also vaccinated with diphtheria vaccine toxoid, pertussis vaccine acellular 5-component, tetanus vaccine toxoid (ADACEL), dose number in series reported as N/A, lot # U5850AA, expiration date 17-JAN-2020, administered intramuscularly in left arm (strength and dose were not provided); with influenza vaccine inact split 4v (FLUZONE QUADRIVALENT), dose number in series reported as N/A, lot number U6648CA, administered intramuscularly in left arm (strength, dose, expiry date were not provided); and with meningococcal vaccine a/c/y/w conj (dip tox) (MENACTRA), dose number in series reported as N/A, lot # U6153AA, administered intramuscularly in right arm (strength, dose, expiry date were not provided). All suspect vaccines were given for prophylaxis.  On 19-FEB-2020, injections listed above were given. Dates and lots were checked before they were given. The reporter did not catch that diphtheria vaccine toxoid, pertussis vaccine acellular 5-component, tetanus vaccine toxoid (ADACEL) (reported as "Tdap") had expired on 17-JAN-2020. The reporter was thinking that it was good until next January. All injections were given without problems. When documenting in system was when he realized that it was in fact past its expiration date. The reporter notified his NP that he worked under along with the Office Manager. He contacted the mom of the patient and she reported no side effects noted other then the patient's arms were sore for a couple of days due to receiving 2 shots in each. The patient recovered from the event on unspecified date in February 2020.   The causal relationship between the event and suspect vaccines was unknown.  Follow-up information was received from a healthcare professional on 19-SEP-2022. It was reported that the patient was not a patient at that clinic.
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: Sars-Cov-2 positive; Sars-Cov-2 positive; This is a spontaneous report received from a contactable reporter (Other HCP). The reporter is the patient.  A 78-year-old female patient received BNT162b2 (BNT162B2), on 23Feb2021 at 08:30 as dose 1, single (Lot number: EN5318), in right arm and on 15Mar2021 at 08:30 as dose 2, single (Lot number: EN6207) at the age of 78 years, in right arm, all intramuscular for COVID-19 immunization. The patient's relevant medical history included: "Patient allergies: Fungus" (unspecified if ongoing); "Mold" (unspecified if ongoing); "tree birch" (unspecified if ongoing); "Maple, oak" (unspecified if ongoing); "egg plant" (unspecified if ongoing); "wheat" (unspecified if ongoing); "str. beans, strawberries, oranges, tomato" (unspecified if ongoing); "chocolate" (unspecified if ongoing); "sulfa" (unspecified if ongoing); "penicillin" (unspecified if ongoing). There were no concomitant medications. Past drug history included: Cipro, reaction: "Ankle swelling"; Azithromax, reaction: "Body Welts"; Tetracycline, reaction: "Patient allergies". The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 06Oct2021, outcome "not recovered" and all described as "Sars-Cov-2 positive". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (06Oct2021) Positive.; Sender's Comments: The vaccine efficacy varies from one patient to another and can be affected by different factors; however, a contributory role of the suspect vaccine BNT162B2 to vaccination failure and COVID-19 cannot be ruled out.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Drug ineffective, Suspected COVID-19
Clinical narrative: Caught COVID for the first time on 28Aug2022; Caught COVID for the first time on 28Aug2022; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID. The reporter is the patient.  A 41-year-old female patient (unknown if pregnant) received BNT162b2 (BNT162B2), on 11Apr2021 at 12:00 as dose 1, single (Lot number: EW0153), in right arm, on 02May2021 at 12:15 as dose 2, single (Lot number: EW0167), in right arm and on 15Nov2021 at 15:15 as dose 3 (booster), single (Lot number: FF2593) at the age of 40 years, in left arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant) all with onset 28Aug2022, outcome "unknown" and all described as "Caught COVID for the first time on 28Aug2022".  Additional information: Patient was vaccinated. Booster shot. She caught COVID for the first time on 28Aug2022.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Herpes zoster, SARS-CoV-2 test
Clinical narrative: Caught COVID for the first time on 28Aug2022; Caught COVID for the first time on 28Aug2022; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID. The reporter is the patient.  A 41-year-old female patient (unknown if pregnant) received BNT162b2 (BNT162B2), on 11Apr2021 at 12:00 as dose 1, single (Lot number: EW0153), in right arm, on 02May2021 at 12:15 as dose 2, single (Lot number: EW0167), in right arm and on 15Nov2021 at 15:15 as dose 3 (booster), single (Lot number: FF2593) at the age of 40 years, in left arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant) all with onset 28Aug2022, outcome "unknown" and all described as "Caught COVID for the first time on 28Aug2022".  Additional information: Patient was vaccinated. Booster shot. She caught COVID for the first time on 28Aug2022.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Drug ineffective, Suspected COVID-19
Clinical narrative: Shingles; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID: (005570). The reporter is the patient.  A 41-year-old female patient (unknown if pregnant) received BNT162b2 (BNT162B2), on 15Nov2021 at 15:15 as dose 3 (booster), single (Lot number: FF2593) at the age of 40 years, in left arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: BNT162b2 (Dose 1, single at 12:00 in right arm; Lot number: EW0153), administration date: 11Apr2021, when the patient was 40-year-old, for Covid-19 immunization; BNT162b2 (Dose 2, single at 12:15 in right arm; Lot number: EW0167), administration date: 02May2021, when the patient was 41-year-old, for Covid-19 immunization. The following information was reported: HERPES ZOSTER (non-serious) with onset 10Sep2022, outcome "unknown", described as "Shingles". Relevant laboratory tests and procedures are available in the appropriate section. Additional information: Patient was vaccinated; booster shot. Patient got COVID for the first time on 28Aug2022 and had shingles starting on 10Sep2022. Patient states she shouldn't be dealing with shingles or missing work because of it.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Herpes zoster, SARS-CoV-2 test
Clinical narrative: Shingles; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID: (005570). The reporter is the patient.  A 41-year-old female patient (unknown if pregnant) received BNT162b2 (BNT162B2), on 15Nov2021 at 15:15 as dose 3 (booster), single (Lot number: FF2593) at the age of 40 years, in left arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: BNT162b2 (Dose 1, single at 12:00 in right arm; Lot number: EW0153), administration date: 11Apr2021, when the patient was 40-year-old, for Covid-19 immunization; BNT162b2 (Dose 2, single at 12:15 in right arm; Lot number: EW0167), administration date: 02May2021, when the patient was 41-year-old, for Covid-19 immunization. The following information was reported: HERPES ZOSTER (non-serious) with onset 10Sep2022, outcome "unknown", described as "Shingles". Relevant laboratory tests and procedures are available in the appropriate section. Additional information: Patient was vaccinated; booster shot. Patient got COVID for the first time on 28Aug2022 and had shingles starting on 10Sep2022. Patient states she shouldn't be dealing with shingles or missing work because of it.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Death, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission  after 1 Janssen vaccine; patient expired
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Blood test, Computerised tomogram, Dermatitis, Dizziness, Feeling abnormal
Clinical narrative: Started with inflammation and burning pain in the middle of the back. Swollen Lymphs, loss of appetite, night sweats, Blurry Vision, Cutaneous hives and skin flushing. Joint pain, fatigue, brain fog. Currently following up with multiple specialists, suspected autoimmune condition. Was on Hydroxychloroquine for three months.
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Feeling hot, Inflammation, Magnetic resonance imaging, Skin discolouration, Skin warm
Clinical narrative: Started with inflammation and burning pain in the middle of the back. Swollen Lymphs, loss of appetite, night sweats, Blurry Vision, Cutaneous hives and skin flushing. Joint pain, fatigue, brain fog. Currently following up with multiple specialists, suspected autoimmune condition. Was on Hydroxychloroquine for three months.
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Vision blurred
Clinical narrative: Started with inflammation and burning pain in the middle of the back. Swollen Lymphs, loss of appetite, night sweats, Blurry Vision, Cutaneous hives and skin flushing. Joint pain, fatigue, brain fog. Currently following up with multiple specialists, suspected autoimmune condition. Was on Hydroxychloroquine for three months.
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Arthralgia, Autoimmune disorder, Biopsy skin, Blood test, Computerised tomogram
Clinical narrative: Started with inflammation and burning pain in the middle of the back. Swollen Lymphs, loss of appetite, night sweats, Blurry Vision, Cutaneous hives and skin flushing. Joint pain, fatigue, brain fog. Currently following up with multiple specialists, suspected autoimmune condition. Was on Hydroxychloroquine for three months.
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Decreased appetite, Fatigue, Feeling abnormal, Flushing, Inflammation
Clinical narrative: Started with inflammation and burning pain in the middle of the back. Swollen Lymphs, loss of appetite, night sweats, Blurry Vision, Cutaneous hives and skin flushing. Joint pain, fatigue, brain fog. Currently following up with multiple specialists, suspected autoimmune condition. Was on Hydroxychloroquine for three months.
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Laboratory test, Lymphadenopathy, Magnetic resonance imaging, Night sweats, Pain
Clinical narrative: Started with inflammation and burning pain in the middle of the back. Swollen Lymphs, loss of appetite, night sweats, Blurry Vision, Cutaneous hives and skin flushing. Joint pain, fatigue, brain fog. Currently following up with multiple specialists, suspected autoimmune condition. Was on Hydroxychloroquine for three months.
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Urticaria, Vision blurred, X-ray
Clinical narrative: Started with inflammation and burning pain in the middle of the back. Swollen Lymphs, loss of appetite, night sweats, Blurry Vision, Cutaneous hives and skin flushing. Joint pain, fatigue, brain fog. Currently following up with multiple specialists, suspected autoimmune condition. Was on Hydroxychloroquine for three months.
Age: 59.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: moderately severe tinnitus in both ears; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 59-year-old male patient received BNT162b2 (BNT162B2), on 27Sep2021 at 09:00 as dose 3 (booster), single (Lot number: 301SSBA) at the age of 59 years intramuscular, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: LISI. Past drug history included: Known allergies: levoquin, reaction(s): "Allergy". Vaccination history included: BNT162b2 (Dose Number: 1, Batch/Lot No: EK9231, Location of injection: Arm Left, Vaccine Administration Time: 09:00 AM, Route of Administration: Intramuscular), administration date: 11Jan2021, when the patient was 58-year-old, for COVID-19 immunization, reaction(s): "positive for COVID-19 on 17Mar2022"; BNT162b2 (Dose Number: 2, Batch/Lot No: EL3245, Location of injection: Arm Left, Vaccine Administration Time: 04:00 PM, Route of Administration: Intramuscular), administration date: 03Feb2021, when the patient was 58-year-old, for COVID-19 immunization, reaction(s): "I developed a hissing and ringing in both ears and was diagnosed with tinnitus", "positive for COVID-19 on 17Mar2022". The following information was reported: TINNITUS (non-serious) with onset 03Nov2021 at 16:00, outcome "not recovered", described as "moderately severe tinnitus in both ears". The event "moderately severe tinnitus in both ears" required physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of tinnitus.  Additional information: BNT162b2 was Pfizer Brand. Patient did not received other vaccine in four weeks. Other medications in two weeks included Gemofirbnoprilozil and Lisi.  No COVID prior vaccination. COVID tested post vaccination. The report was considered non-serious.   Follow-up attempts are completed. No further information is expected.
Age: 59.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: SARS-CoV-2 test, Tinnitus
Clinical narrative: moderately severe tinnitus in both ears; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 59-year-old male patient received BNT162b2 (BNT162B2), on 27Sep2021 at 09:00 as dose 3 (booster), single (Lot number: 301SSBA) at the age of 59 years intramuscular, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: LISI. Past drug history included: Known allergies: levoquin, reaction(s): "Allergy". Vaccination history included: BNT162b2 (Dose Number: 1, Batch/Lot No: EK9231, Location of injection: Arm Left, Vaccine Administration Time: 09:00 AM, Route of Administration: Intramuscular), administration date: 11Jan2021, when the patient was 58-year-old, for COVID-19 immunization, reaction(s): "positive for COVID-19 on 17Mar2022"; BNT162b2 (Dose Number: 2, Batch/Lot No: EL3245, Location of injection: Arm Left, Vaccine Administration Time: 04:00 PM, Route of Administration: Intramuscular), administration date: 03Feb2021, when the patient was 58-year-old, for COVID-19 immunization, reaction(s): "I developed a hissing and ringing in both ears and was diagnosed with tinnitus", "positive for COVID-19 on 17Mar2022". The following information was reported: TINNITUS (non-serious) with onset 03Nov2021 at 16:00, outcome "not recovered", described as "moderately severe tinnitus in both ears". The event "moderately severe tinnitus in both ears" required physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of tinnitus.  Additional information: BNT162b2 was Pfizer Brand. Patient did not received other vaccine in four weeks. Other medications in two weeks included Gemofirbnoprilozil and Lisi.  No COVID prior vaccination. COVID tested post vaccination. The report was considered non-serious.   Follow-up attempts are completed. No further information is expected.
Age: 75.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Patient received two vaccines; admitted with breakthrough case and expired
Age: 75.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Death, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Patient received two vaccines; admitted with breakthrough case and expired
Age: 89.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Patient admitted having received 2 vaccines; patient expired
Age: 89.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Death, SARS-CoV-2 test positive
Clinical narrative: Patient admitted having received 2 vaccines; patient expired
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Death, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Patient received two vaccines; was admitted to facility and expired
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Death, SARS-CoV-2 test positive
Clinical narrative: Patient received two vaccines; was admitted to facility and expired
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Death, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Patient admitted to facility with three COVID vaccines received; patient expired.
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Death, SARS-CoV-2 test positive
Clinical narrative: Patient admitted to facility with three COVID vaccines received; patient expired.
Age: 81.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Patient admitted to facility  having received three vaccines; patient expired
Age: 81.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Death, SARS-CoV-2 test positive
Clinical narrative: Patient admitted to facility  having received three vaccines; patient expired
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Death, Laboratory test abnormal
Clinical narrative: Breakthrough case admission after 2 vaccines; patient expired
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Death, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 2 vaccines; patient expired
Age: 69.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dyspnoea, Pyrexia
Clinical narrative: Patient is a 70 y.o.male patient of CNP with history of copd, DM, diverticulosis, glaucoma, gout, HLD, HTN, OSA presented with SOB after being diagnosed with COVID 8 days PTA.    Acute respiratory failure with hypoxia secondary to COVID 19 Pneumonia Covid-19 Virus Infection Date of onset of symptoms: 7/10/22 Symptoms present on admission: SOB, fever Date of covid positive test: 7/11/22 Vaccination status: vaccinated Imaging: CTPA - ground glass opacities Oxygen requirements on admission: 2L Current oxygen requirements: Room air Medical therapy: remdesivir and steroids Consultants following: ID Anticipated special isolation end date: Per ID note isolation can be discontinued Continue bronchodilators and antitussives.  Monitor inflammatory markers.   Patient discharged home in stable condition no further medication discharge patient use oxygen as needed   Sepsis secondary to COVID Present on admission. He was tachycardic and tachypneic. Likely due to COVID-pneumonia. Negative culture data. Continue management as above.   COPD Exacerbated by COVID. Continue steroid as current. On home inhalers?Spiriva and Breo Ellipta/Symbicort.   OSA Just started CPAP on 7/11 Antitussives as needed, analgesics for CP. Restart CPAP if able to tolerate.   Diabetes mellitus, type 2 Home metformin is on hold. Continue SSI, adjust bedtime Lantus Elevated troponin: Likely type II MI from respiratory distress/COVID. Currently no chest pain. Troponin I 111-> 94. Continue to monitor.  HTN: BP is better controlled. Continue losartan.
Age: 69.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Acute myocardial infarction, Acute respiratory failure, Angiogram pulmonary abnormal, COVID-19, COVID-19 pneumonia
Clinical narrative: Patient is a 70 y.o.male patient of CNP with history of copd, DM, diverticulosis, glaucoma, gout, HLD, HTN, OSA presented with SOB after being diagnosed with COVID 8 days PTA.    Acute respiratory failure with hypoxia secondary to COVID 19 Pneumonia Covid-19 Virus Infection Date of onset of symptoms: 7/10/22 Symptoms present on admission: SOB, fever Date of covid positive test: 7/11/22 Vaccination status: vaccinated Imaging: CTPA - ground glass opacities Oxygen requirements on admission: 2L Current oxygen requirements: Room air Medical therapy: remdesivir and steroids Consultants following: ID Anticipated special isolation end date: Per ID note isolation can be discontinued Continue bronchodilators and antitussives.  Monitor inflammatory markers.   Patient discharged home in stable condition no further medication discharge patient use oxygen as needed   Sepsis secondary to COVID Present on admission. He was tachycardic and tachypneic. Likely due to COVID-pneumonia. Negative culture data. Continue management as above.   COPD Exacerbated by COVID. Continue steroid as current. On home inhalers?Spiriva and Breo Ellipta/Symbicort.   OSA Just started CPAP on 7/11 Antitussives as needed, analgesics for CP. Restart CPAP if able to tolerate.   Diabetes mellitus, type 2 Home metformin is on hold. Continue SSI, adjust bedtime Lantus Elevated troponin: Likely type II MI from respiratory distress/COVID. Currently no chest pain. Troponin I 111-> 94. Continue to monitor.  HTN: BP is better controlled. Continue losartan.
Age: 69.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Chest pain, Chronic obstructive pulmonary disease, Condition aggravated, Culture negative, Dyspnoea
Clinical narrative: Patient is a 70 y.o.male patient of CNP with history of copd, DM, diverticulosis, glaucoma, gout, HLD, HTN, OSA presented with SOB after being diagnosed with COVID 8 days PTA.    Acute respiratory failure with hypoxia secondary to COVID 19 Pneumonia Covid-19 Virus Infection Date of onset of symptoms: 7/10/22 Symptoms present on admission: SOB, fever Date of covid positive test: 7/11/22 Vaccination status: vaccinated Imaging: CTPA - ground glass opacities Oxygen requirements on admission: 2L Current oxygen requirements: Room air Medical therapy: remdesivir and steroids Consultants following: ID Anticipated special isolation end date: Per ID note isolation can be discontinued Continue bronchodilators and antitussives.  Monitor inflammatory markers.   Patient discharged home in stable condition no further medication discharge patient use oxygen as needed   Sepsis secondary to COVID Present on admission. He was tachycardic and tachypneic. Likely due to COVID-pneumonia. Negative culture data. Continue management as above.   COPD Exacerbated by COVID. Continue steroid as current. On home inhalers?Spiriva and Breo Ellipta/Symbicort.   OSA Just started CPAP on 7/11 Antitussives as needed, analgesics for CP. Restart CPAP if able to tolerate.   Diabetes mellitus, type 2 Home metformin is on hold. Continue SSI, adjust bedtime Lantus Elevated troponin: Likely type II MI from respiratory distress/COVID. Currently no chest pain. Troponin I 111-> 94. Continue to monitor.  HTN: BP is better controlled. Continue losartan.
Age: 69.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Lung opacity, Positive airway pressure therapy, Pyrexia, Respiratory distress, SARS-CoV-2 test positive
Clinical narrative: Patient is a 70 y.o.male patient of CNP with history of copd, DM, diverticulosis, glaucoma, gout, HLD, HTN, OSA presented with SOB after being diagnosed with COVID 8 days PTA.    Acute respiratory failure with hypoxia secondary to COVID 19 Pneumonia Covid-19 Virus Infection Date of onset of symptoms: 7/10/22 Symptoms present on admission: SOB, fever Date of covid positive test: 7/11/22 Vaccination status: vaccinated Imaging: CTPA - ground glass opacities Oxygen requirements on admission: 2L Current oxygen requirements: Room air Medical therapy: remdesivir and steroids Consultants following: ID Anticipated special isolation end date: Per ID note isolation can be discontinued Continue bronchodilators and antitussives.  Monitor inflammatory markers.   Patient discharged home in stable condition no further medication discharge patient use oxygen as needed   Sepsis secondary to COVID Present on admission. He was tachycardic and tachypneic. Likely due to COVID-pneumonia. Negative culture data. Continue management as above.   COPD Exacerbated by COVID. Continue steroid as current. On home inhalers?Spiriva and Breo Ellipta/Symbicort.   OSA Just started CPAP on 7/11 Antitussives as needed, analgesics for CP. Restart CPAP if able to tolerate.   Diabetes mellitus, type 2 Home metformin is on hold. Continue SSI, adjust bedtime Lantus Elevated troponin: Likely type II MI from respiratory distress/COVID. Currently no chest pain. Troponin I 111-> 94. Continue to monitor.  HTN: BP is better controlled. Continue losartan.
Age: 69.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Sepsis, Tachycardia, Tachypnoea, Troponin I increased, Troponin increased
Clinical narrative: Patient is a 70 y.o.male patient of CNP with history of copd, DM, diverticulosis, glaucoma, gout, HLD, HTN, OSA presented with SOB after being diagnosed with COVID 8 days PTA.    Acute respiratory failure with hypoxia secondary to COVID 19 Pneumonia Covid-19 Virus Infection Date of onset of symptoms: 7/10/22 Symptoms present on admission: SOB, fever Date of covid positive test: 7/11/22 Vaccination status: vaccinated Imaging: CTPA - ground glass opacities Oxygen requirements on admission: 2L Current oxygen requirements: Room air Medical therapy: remdesivir and steroids Consultants following: ID Anticipated special isolation end date: Per ID note isolation can be discontinued Continue bronchodilators and antitussives.  Monitor inflammatory markers.   Patient discharged home in stable condition no further medication discharge patient use oxygen as needed   Sepsis secondary to COVID Present on admission. He was tachycardic and tachypneic. Likely due to COVID-pneumonia. Negative culture data. Continue management as above.   COPD Exacerbated by COVID. Continue steroid as current. On home inhalers?Spiriva and Breo Ellipta/Symbicort.   OSA Just started CPAP on 7/11 Antitussives as needed, analgesics for CP. Restart CPAP if able to tolerate.   Diabetes mellitus, type 2 Home metformin is on hold. Continue SSI, adjust bedtime Lantus Elevated troponin: Likely type II MI from respiratory distress/COVID. Currently no chest pain. Troponin I 111-> 94. Continue to monitor.  HTN: BP is better controlled. Continue losartan.
Age: 58.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Patient admitted to facility with three vaccines received; expired
Age: 58.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Death, SARS-CoV-2 test positive
Clinical narrative: Patient admitted to facility with three vaccines received; expired
Age: 83.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: COVID vaccine breakthrough case. Moderna 2/14/21 038K20A, 3/14/21 030A21A and boosted Pfizer 12/2/21 FJ 8757 and 5/19/22 FK9894
Age: 73.0
Sex: F
Vaccine: COVID19-2, COVID19-2
Symptoms: Blood pressure increased, Chest discomfort, Heart rate increased, Palpitations, Tremor
Clinical narrative: Woke up at 5:30 am with severe chest and upper back pressure.  Took my BP - 215/95 - two other times which were about the same reading.   I called a neighbor to come over.  By the time she arrived (10 minutes) I was severely shaking and experiencing chills.  Because my BP continued to be very high, she  immediately took me to the Emergency site (about a mile from home).  They immediately took me in and did an EKG and bloodwork.  After several hours I was transported to Medical Center to be admitted.  Multiple tests were taken, including chest x-ray, ECHO exam, pharmacologic stress test and an angiogram.  I was in the hospital for 2.5 days; had bloodwork taken repeatedly; started receiving blood pressure medicine which was successful in finally getting my blood pressure down.  I was discharged on 9/10/22 with a prescription for Lisinopril for my BP.  As a footnote, the doctor who did the angiogram told me my heart was in good shape and he "speculated" that what I experienced was a result of the COVID19 booster I had received on 9/7/22, although he couldn't say for sure.  I was encouraged to let the pharmacy know and the pharmacy gave me the VAERS information to submit a report.
Age: 73.0
Sex: F
Vaccine: COVID19-2, COVID19-2
Symptoms: Angiogram, Blood test, Blood thyroid stimulating hormone, Brain natriuretic peptide, Cardiac stress test
Clinical narrative: Woke up at 5:30 am with severe chest and upper back pressure.  Took my BP - 215/95 - two other times which were about the same reading.   I called a neighbor to come over.  By the time she arrived (10 minutes) I was severely shaking and experiencing chills.  Because my BP continued to be very high, she  immediately took me to the Emergency site (about a mile from home).  They immediately took me in and did an EKG and bloodwork.  After several hours I was transported to Medical Center to be admitted.  Multiple tests were taken, including chest x-ray, ECHO exam, pharmacologic stress test and an angiogram.  I was in the hospital for 2.5 days; had bloodwork taken repeatedly; started receiving blood pressure medicine which was successful in finally getting my blood pressure down.  I was discharged on 9/10/22 with a prescription for Lisinopril for my BP.  As a footnote, the doctor who did the angiogram told me my heart was in good shape and he "speculated" that what I experienced was a result of the COVID19 booster I had received on 9/7/22, although he couldn't say for sure.  I was encouraged to let the pharmacy know and the pharmacy gave me the VAERS information to submit a report.
Age: 73.0
Sex: F
Vaccine: COVID19-2, COVID19-2
Symptoms: Chest X-ray, Chest discomfort, Chills, Condition aggravated, Differential white blood cell count
Clinical narrative: Woke up at 5:30 am with severe chest and upper back pressure.  Took my BP - 215/95 - two other times which were about the same reading.   I called a neighbor to come over.  By the time she arrived (10 minutes) I was severely shaking and experiencing chills.  Because my BP continued to be very high, she  immediately took me to the Emergency site (about a mile from home).  They immediately took me in and did an EKG and bloodwork.  After several hours I was transported to Medical Center to be admitted.  Multiple tests were taken, including chest x-ray, ECHO exam, pharmacologic stress test and an angiogram.  I was in the hospital for 2.5 days; had bloodwork taken repeatedly; started receiving blood pressure medicine which was successful in finally getting my blood pressure down.  I was discharged on 9/10/22 with a prescription for Lisinopril for my BP.  As a footnote, the doctor who did the angiogram told me my heart was in good shape and he "speculated" that what I experienced was a result of the COVID19 booster I had received on 9/7/22, although he couldn't say for sure.  I was encouraged to let the pharmacy know and the pharmacy gave me the VAERS information to submit a report.
Age: 73.0
Sex: F
Vaccine: COVID19-2, COVID19-2
Symptoms: Echocardiogram, Electrocardiogram, Fibrin D dimer, Full blood count, Hypertension
Clinical narrative: Woke up at 5:30 am with severe chest and upper back pressure.  Took my BP - 215/95 - two other times which were about the same reading.   I called a neighbor to come over.  By the time she arrived (10 minutes) I was severely shaking and experiencing chills.  Because my BP continued to be very high, she  immediately took me to the Emergency site (about a mile from home).  They immediately took me in and did an EKG and bloodwork.  After several hours I was transported to Medical Center to be admitted.  Multiple tests were taken, including chest x-ray, ECHO exam, pharmacologic stress test and an angiogram.  I was in the hospital for 2.5 days; had bloodwork taken repeatedly; started receiving blood pressure medicine which was successful in finally getting my blood pressure down.  I was discharged on 9/10/22 with a prescription for Lisinopril for my BP.  As a footnote, the doctor who did the angiogram told me my heart was in good shape and he "speculated" that what I experienced was a result of the COVID19 booster I had received on 9/7/22, although he couldn't say for sure.  I was encouraged to let the pharmacy know and the pharmacy gave me the VAERS information to submit a report.
Age: 73.0
Sex: F
Vaccine: COVID19-2, COVID19-2
Symptoms: Immunisation reaction, Influenza A virus test, Influenza B virus test, Metabolic function test, Platelet count
Clinical narrative: Woke up at 5:30 am with severe chest and upper back pressure.  Took my BP - 215/95 - two other times which were about the same reading.   I called a neighbor to come over.  By the time she arrived (10 minutes) I was severely shaking and experiencing chills.  Because my BP continued to be very high, she  immediately took me to the Emergency site (about a mile from home).  They immediately took me in and did an EKG and bloodwork.  After several hours I was transported to Medical Center to be admitted.  Multiple tests were taken, including chest x-ray, ECHO exam, pharmacologic stress test and an angiogram.  I was in the hospital for 2.5 days; had bloodwork taken repeatedly; started receiving blood pressure medicine which was successful in finally getting my blood pressure down.  I was discharged on 9/10/22 with a prescription for Lisinopril for my BP.  As a footnote, the doctor who did the angiogram told me my heart was in good shape and he "speculated" that what I experienced was a result of the COVID19 booster I had received on 9/7/22, although he couldn't say for sure.  I was encouraged to let the pharmacy know and the pharmacy gave me the VAERS information to submit a report.
Age: 73.0
Sex: F
Vaccine: COVID19-2, COVID19-2
Symptoms: SARS-CoV-2 test, Thyroxine free, Tremor, Troponin
Clinical narrative: Woke up at 5:30 am with severe chest and upper back pressure.  Took my BP - 215/95 - two other times which were about the same reading.   I called a neighbor to come over.  By the time she arrived (10 minutes) I was severely shaking and experiencing chills.  Because my BP continued to be very high, she  immediately took me to the Emergency site (about a mile from home).  They immediately took me in and did an EKG and bloodwork.  After several hours I was transported to Medical Center to be admitted.  Multiple tests were taken, including chest x-ray, ECHO exam, pharmacologic stress test and an angiogram.  I was in the hospital for 2.5 days; had bloodwork taken repeatedly; started receiving blood pressure medicine which was successful in finally getting my blood pressure down.  I was discharged on 9/10/22 with a prescription for Lisinopril for my BP.  As a footnote, the doctor who did the angiogram told me my heart was in good shape and he "speculated" that what I experienced was a result of the COVID19 booster I had received on 9/7/22, although he couldn't say for sure.  I was encouraged to let the pharmacy know and the pharmacy gave me the VAERS information to submit a report.
Age: 53.0
Sex: M
Vaccine: COVID19-2, COVID19, COVID19-2
Symptoms: Dizziness, Ear discomfort, Pain in extremity, Vertigo
Clinical narrative: Vertigo; Dizziness; This spontaneous case was reported by a patient and describes the occurrence of VERTIGO (Vertigo) and DIZZINESS (Dizziness) in a 53-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7140C) for COVID-19 vaccination.     Patient did not had any allergies.  Concomitant products included ATORVASTATIN CALCIUM (LIPITOR) for an unknown indication.    On 09-Sep-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 13-Sep-2022, the patient experienced VERTIGO (Vertigo) and DIZZINESS (Dizziness). The patient was treated with MECLIZINE HCL at an unspecified dose and frequency. At the time of the report, VERTIGO (Vertigo) and DIZZINESS (Dizziness) outcome was unknown.            Patient DOB was reported.  It was reported that the caller was a consumer who had the latest Moderna shot on 09-Sep-2022.   At the same time patient had received unspecified flu shot.
Age: 53.0
Sex: M
Vaccine: COVID19-2, COVID19, COVID19-2
Symptoms: Acoustic stimulation tests normal, Dizziness, Vertigo
Clinical narrative: Vertigo; Dizziness; This spontaneous case was reported by a patient and describes the occurrence of VERTIGO (Vertigo) and DIZZINESS (Dizziness) in a 53-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7140C) for COVID-19 vaccination.     Patient did not had any allergies.  Concomitant products included ATORVASTATIN CALCIUM (LIPITOR) for an unknown indication.    On 09-Sep-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 13-Sep-2022, the patient experienced VERTIGO (Vertigo) and DIZZINESS (Dizziness). The patient was treated with MECLIZINE HCL at an unspecified dose and frequency. At the time of the report, VERTIGO (Vertigo) and DIZZINESS (Dizziness) outcome was unknown.            Patient DOB was reported.  It was reported that the caller was a consumer who had the latest Moderna shot on 09-Sep-2022.   At the same time patient had received unspecified flu shot.
Age: 53.0
Sex: M
Vaccine: COVID19-2, COVID19, COVID19-2
Symptoms: Dizziness, Vertigo
Clinical narrative: Vertigo; Dizziness; This spontaneous case was reported by a patient and describes the occurrence of VERTIGO (Vertigo) and DIZZINESS (Dizziness) in a 53-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7140C) for COVID-19 vaccination.     Patient did not had any allergies.  Concomitant products included ATORVASTATIN CALCIUM (LIPITOR) for an unknown indication.    On 09-Sep-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 13-Sep-2022, the patient experienced VERTIGO (Vertigo) and DIZZINESS (Dizziness). The patient was treated with MECLIZINE HCL at an unspecified dose and frequency. At the time of the report, VERTIGO (Vertigo) and DIZZINESS (Dizziness) outcome was unknown.            Patient DOB was reported.  It was reported that the caller was a consumer who had the latest Moderna shot on 09-Sep-2022.   At the same time patient had received unspecified flu shot.
Age: 12.0
Sex: M
Vaccine: COVID19-2, COVID19-2
Symptoms: Blood creatine phosphokinase normal, Blood culture negative, Borrelia test negative, C-reactive protein increased, Cardiac telemetry abnormal
Clinical narrative: This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the parent. A 12-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 10Sep2022 at 19:30 as dose 3 (booster), single (Lot number: GH9694) at the age of 12 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Bnt162b2 (DOSE 2), for COVID-19 Immunization; Bnt162b2 (DOSE 1), for COVID-19 Immunization. The following information was reported: CHEST PAIN (hospitalization) with onset 13Sep2022 at 22:00, outcome "recovering"; PERICARDITIS (hospitalization, medically significant) with onset 13Sep2022 at 22:00, outcome "recovering", described as "Peri-Carditis"; HEADACHE (hospitalization) with onset 13Sep2022 at 22:00, outcome "recovering"; HYPERHIDROSIS (hospitalization) with onset 13Sep2022 at 22:00, outcome "recovering", described as "sweating"; CHEST DISCOMFORT (hospitalization) with onset 13Sep2022 at 22:00, outcome "recovering", described as "tightness in chest". The patient was hospitalized for pericarditis, chest discomfort, chest pain, headache, hyperhidrosis (hospitalization duration: 3 day(s)). The events "peri-carditis", "tightness in chest", "chest pain", "headache" and "sweating" required emergency room visit. Therapeutic measures were taken as a result of pericarditis, chest discomfort, chest pain, headache, hyperhidrosis and the treatment included NSAID and Antacid.
Age: 12.0
Sex: M
Vaccine: COVID19-2, COVID19-2
Symptoms: Chest X-ray normal, Chest pain, Cytomegalovirus test negative, Echocardiogram normal, Electrocardiogram PR prolongation
Clinical narrative: This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the parent. A 12-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 10Sep2022 at 19:30 as dose 3 (booster), single (Lot number: GH9694) at the age of 12 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Bnt162b2 (DOSE 2), for COVID-19 Immunization; Bnt162b2 (DOSE 1), for COVID-19 Immunization. The following information was reported: CHEST PAIN (hospitalization) with onset 13Sep2022 at 22:00, outcome "recovering"; PERICARDITIS (hospitalization, medically significant) with onset 13Sep2022 at 22:00, outcome "recovering", described as "Peri-Carditis"; HEADACHE (hospitalization) with onset 13Sep2022 at 22:00, outcome "recovering"; HYPERHIDROSIS (hospitalization) with onset 13Sep2022 at 22:00, outcome "recovering", described as "sweating"; CHEST DISCOMFORT (hospitalization) with onset 13Sep2022 at 22:00, outcome "recovering", described as "tightness in chest". The patient was hospitalized for pericarditis, chest discomfort, chest pain, headache, hyperhidrosis (hospitalization duration: 3 day(s)). The events "peri-carditis", "tightness in chest", "chest pain", "headache" and "sweating" required emergency room visit. Therapeutic measures were taken as a result of pericarditis, chest discomfort, chest pain, headache, hyperhidrosis and the treatment included NSAID and Antacid.
Age: 12.0
Sex: M
Vaccine: COVID19-2, COVID19-2
Symptoms: Electrocardiogram normal, Enterovirus test negative, Epstein-Barr virus test negative, Fatigue, Full blood count normal
Clinical narrative: This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the parent. A 12-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 10Sep2022 at 19:30 as dose 3 (booster), single (Lot number: GH9694) at the age of 12 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Bnt162b2 (DOSE 2), for COVID-19 Immunization; Bnt162b2 (DOSE 1), for COVID-19 Immunization. The following information was reported: CHEST PAIN (hospitalization) with onset 13Sep2022 at 22:00, outcome "recovering"; PERICARDITIS (hospitalization, medically significant) with onset 13Sep2022 at 22:00, outcome "recovering", described as "Peri-Carditis"; HEADACHE (hospitalization) with onset 13Sep2022 at 22:00, outcome "recovering"; HYPERHIDROSIS (hospitalization) with onset 13Sep2022 at 22:00, outcome "recovering", described as "sweating"; CHEST DISCOMFORT (hospitalization) with onset 13Sep2022 at 22:00, outcome "recovering", described as "tightness in chest". The patient was hospitalized for pericarditis, chest discomfort, chest pain, headache, hyperhidrosis (hospitalization duration: 3 day(s)). The events "peri-carditis", "tightness in chest", "chest pain", "headache" and "sweating" required emergency room visit. Therapeutic measures were taken as a result of pericarditis, chest discomfort, chest pain, headache, hyperhidrosis and the treatment included NSAID and Antacid.
Age: 12.0
Sex: M
Vaccine: COVID19-2, COVID19-2
Symptoms: Laboratory test, Pyrexia, Troponin increased
Clinical narrative: This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the parent. A 12-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 10Sep2022 at 19:30 as dose 3 (booster), single (Lot number: GH9694) at the age of 12 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Bnt162b2 (DOSE 2), for COVID-19 Immunization; Bnt162b2 (DOSE 1), for COVID-19 Immunization. The following information was reported: CHEST PAIN (hospitalization) with onset 13Sep2022 at 22:00, outcome "recovering"; PERICARDITIS (hospitalization, medically significant) with onset 13Sep2022 at 22:00, outcome "recovering", described as "Peri-Carditis"; HEADACHE (hospitalization) with onset 13Sep2022 at 22:00, outcome "recovering"; HYPERHIDROSIS (hospitalization) with onset 13Sep2022 at 22:00, outcome "recovering", described as "sweating"; CHEST DISCOMFORT (hospitalization) with onset 13Sep2022 at 22:00, outcome "recovering", described as "tightness in chest". The patient was hospitalized for pericarditis, chest discomfort, chest pain, headache, hyperhidrosis (hospitalization duration: 3 day(s)). The events "peri-carditis", "tightness in chest", "chest pain", "headache" and "sweating" required emergency room visit. Therapeutic measures were taken as a result of pericarditis, chest discomfort, chest pain, headache, hyperhidrosis and the treatment included NSAID and Antacid.